Form 4: Esperion Therapeutics Director Jay Shepard Reports Acquisition of Shares and Stock Options
SEC Form 4
Director Jay Shepard reports acquiring 23,000 shares of common stock and 32,500 stock options in Esperion Therapeutics.
Summary
- On May 23, 2024, Jay Shepard, a director of Esperion Therapeutics, Inc., reported acquiring 23,000 shares of common stock at $0 and 32,500 stock options with an exercise price of $2.25.
- Following these transactions, Shepard directly owns 51,599 shares of common stock and 32,500 stock options.
- The stock options vest in full on the earlier of May 23, 2025, or the Issuer's next annual meeting of stockholders following May 23, 2024.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine filing and doesn't provide substantial new information about the company's performance.
Positives
- The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring such transactions can provide insights into management's sentiment about the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 05/25/2022 | Date of execution for the Limited Power of Attorney. |
| 05/23/2024 | Date of the reported transactions: acquisition of common stock and stock options. |
| 05/23/2024 | Date of filing the Form 4. |
| 05/23/2025 | Earliest vesting date for the acquired stock options. |
| 05/23/2034 | Expiration date for the acquired stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.